Intrahepatic cholestasis of pregnancy

Intrahepatic cholestasis of pregnancy (ICP) is a cholestatic disorder characterized by (i) pruritus with onset in the second or third trimester of pregnancy, (ii) elevated serum aminotransferases and bile acid levels, and (iii) spontaneous relief of signs and symptoms within two to three weeks after...

Full description

Saved in:
Bibliographic Details
Published in:Orphanet journal of rare diseases 2007-05, Vol.2 (1), p.26-26, Article 26
Main Authors: Pusl, Thomas, Beuers, Ulrich
Format: Article
Language:English
Subjects:
Cholagogues and Choleretics - therapeutic use
Cholestasis
Cholestasis, Intrahepatic - complications
Cholestasis, Intrahepatic - diagnosis
Cholestasis, Intrahepatic - metabolism
Cholestasis, Intrahepatic - therapy
Delivery, Obstetric
Diagnosis, Differential
Estrogens - metabolism
Female
Humans
Jaundice, Obstructive
Pregnancy
Pregnancy Complications - diagnosis
Pregnancy Complications - metabolism
Pregnancy Complications - therapy
Pregnancy Outcome
Pregnancy, Complications of
Prognosis
Pruritus - diagnosis
Pruritus - etiology
Review
Ursodeoxycholic Acid - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intrahepatic cholestasis of pregnancy (ICP) is a cholestatic disorder characterized by (i) pruritus with onset in the second or third trimester of pregnancy, (ii) elevated serum aminotransferases and bile acid levels, and (iii) spontaneous relief of signs and symptoms within two to three weeks after delivery. ICP is observed in 0.4-1% of pregnancies in most areas of Central and Western Europe and North America, while in Chile and Bolivia as well as Scandinavia and the Baltic states roughly 5-15% and 1-2%, respectively, of pregnancies are associated with ICP. Genetic and hormonal factors, but also environmental factors may contribute to the pathogenesis of ICP. Intrahepatic cholestasis of pregnancy increases the risk of preterm delivery (19-60%), meconium staining of amniotic fluid (27%), fetal bradycardia (14%), fetal distress (22-41%), and fetal loss (0.4-4.1%), particularly when associated with fasting serum bile acid levels > 40 micromol/L. The hydrophilic bile acid ursodeoxycholic acid (10-20 mg/kg/d) is today regarded as the first line treatment for intrahepatic cholestasis of pregnancy. Delivery has been recommended in the 38th week when lung maturity has been established.
ISSN:1750-1172
1750-1172
DOI:10.1186/1750-1172-2-26